Summary
On August 28, 2026, the FDA approved MIMRYLO (rusfertide), developed by Protagonist Therapeutics and commercialized by Takeda, for treating erythrocytosis in adults with polycythemia vera.
MIMRYLO is the first approved hepcidin mimetic peptide for PV. It targets the iron-regulation pathway rather than directly inhibiting JAK-STAT signaling or modulating the immune system through interferon.
The FDA approval was based on findings from the global, randomized Phase 3 VERIFY trial (NCT05210790), which enrolled 293 patients with PV.
With its differentiated mechanism and broad label, it could challenge established treatment patterns while intensifying c...
